Correlation Between Xbrane Biopharma and C Rad
Can any of the company-specific risk be diversified away by investing in both Xbrane Biopharma and C Rad at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xbrane Biopharma and C Rad into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Xbrane Biopharma AB and C Rad AB, you can compare the effects of market volatilities on Xbrane Biopharma and C Rad and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xbrane Biopharma with a short position of C Rad. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xbrane Biopharma and C Rad.
Diversification Opportunities for Xbrane Biopharma and C Rad
-0.49 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Xbrane and CRAD-B is -0.49. Overlapping area represents the amount of risk that can be diversified away by holding Xbrane Biopharma AB and C Rad AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on C Rad AB and Xbrane Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xbrane Biopharma AB are associated (or correlated) with C Rad. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of C Rad AB has no effect on the direction of Xbrane Biopharma i.e., Xbrane Biopharma and C Rad go up and down completely randomly.
Pair Corralation between Xbrane Biopharma and C Rad
Assuming the 90 days trading horizon Xbrane Biopharma AB is expected to generate 2.17 times more return on investment than C Rad. However, Xbrane Biopharma is 2.17 times more volatile than C Rad AB. It trades about 0.04 of its potential returns per unit of risk. C Rad AB is currently generating about -0.14 per unit of risk. If you would invest 16.00 in Xbrane Biopharma AB on September 14, 2024 and sell it today you would earn a total of 1.00 from holding Xbrane Biopharma AB or generate 6.25% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Xbrane Biopharma AB vs. C Rad AB
Performance |
Timeline |
Xbrane Biopharma |
C Rad AB |
Xbrane Biopharma and C Rad Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Xbrane Biopharma and C Rad
The main advantage of trading using opposite Xbrane Biopharma and C Rad positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xbrane Biopharma position performs unexpectedly, C Rad can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in C Rad will offset losses from the drop in C Rad's long position.Xbrane Biopharma vs. Hansa Biopharma AB | Xbrane Biopharma vs. Vicore Pharma Holding | Xbrane Biopharma vs. XSpray Pharma AB | Xbrane Biopharma vs. Saniona AB |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Complementary Tools
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Equity Valuation Check real value of public entities based on technical and fundamental data |